The goal is to determine if integration of DCE-MRI and molecular markers improves early prediction of breast cancer response to neoadjuvant chemotherapy (NACT). 49 patients undergoing standard of care NACT had DCE-MRI before and after the first NACT cycle, with 12 of them achieving pathologic complete response (pCR) after NACT. Pharmacokinetic (PK) analysis of DCE-MRI data was performed using the shutter-speed model. Changes in PK parameters were superior to changes in tumor size for early prediction of pCR. The improvement in predictive performance by combining DCE and HR, HER2 molecular markers was statistically significant compared to using MRI markers alone.